GlassScriptPhysician profile
James K Yan
NPI 1588683890
$13,407.39
in general payments reported to CMS, 2019-2025
24 companies · $1,135 in 2025
The $1,135 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,059 · 2020: $655 · 2021: $2,848 · 2022: $840 · 2023: $1,164 · 2024: $2,707 · 2025: $1,135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,742 · Consulting Fee: $1,904 · Honoraria: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,742.29 |
| Consulting Fee | $1,903.50 |
| Honoraria | $360.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $7,094.99 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,903.50 | 2024 | Imfinzi |
| Abbvie INC. | $1,446.10 | 2019-2025 | Linzess, Creon, Viberzi |
| Ironwood Pharmaceuticals, INC | $1,015.94 | 2019-2024 | Linzess |
| Daiichi Sankyo INC. | $360.00 | 2023 | |
| Braintree Laboratories, INC. | $330.49 | 2020-2025 | Sutab, Suflave |
| Celgene Corporation | $255.73 | 2021-2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $210.57 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $140.51 | 2023-2025 | Entyvio |
| Janssen Biotech, INC. | $96.01 | 2024-2025 | Tremfya |
| Qol Medical, LLC | $82.47 | 2022-2025 | Sucraid |
| Aimmune Therapeutics, INC. | $76.58 | 2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $71.97 | 2020-2024 | |
| Ferring Pharmaceuticals INC. | $51.42 | 2019-2023 | Rebyota |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.15 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $33.52 | 2025 | Sutab |
| Lilly USA, LLC | $32.80 | 2024 | Omvoh |
| Endogastric Solutions, INC | $28.96 | 2024 | Esophyx |
| Novo Nordisk INC | $28.25 | 2025 | Wegovy |
| Ardelyx, INC. | $21.64 | 2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $20.83 | 2024 | Voquezna |
| Celltrion USA INC. | $20.37 | 2024 | Vegzelma |
| Exact Sciences Corporation | $19.44 | 2024 | |
| Allergan, INC. | $19.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Yan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.